Insider Buying: Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Purchases $27,792.54 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt purchased 7,851 shares of the stock in a transaction on Thursday, July 2nd. The stock was acquired at an average price of $3.54 per share, with a total value of $27,792.54. Following the acquisition, the insider directly owned 90,407 shares in the company, valued at $320,040.78. This trade represents a 9.51% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total transaction of $65,229.12.
• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.33, for a total value of $35,231.40.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $31,667.22.
• On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.30 per share, for a total transaction of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Down 8.1%

NASDAQ SHPH opened at $3.28 on Friday. The stock has a market cap of $2.09 million, a PE ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $55.90. The business has a 50 day moving average price of $5.15 and a two-hundred day moving average price of $10.18.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter worth about $26,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals during the 4th quarter valued at about $37,000. Ikarian Capital LLC acquired a new position in Shuttle Pharmaceuticals during the 4th quarter valued at about $124,000. Finally, Connective Capital Management LLC bought a new position in Shuttle Pharmaceuticals in the 3rd quarter worth about $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on SHPH. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, July 4th. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .